- Trials with a EudraCT protocol (176)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
176 result(s) found for: Sodium MRI.
Displaying page 8 of 9.
EudraCT Number: 2012-001850-24 | Sponsor Protocol Number: ABCSG_P02 | Start Date*: 2012-08-10 |
Sponsor Name:ABCSG (Austrian Breast & Colorectal Cancer Study Group) | ||
Full Title: A prospective randomized phase II trial of FOLFIRINOX alone versus FOLFIRINOX followed by radiochemotherapy in patients with locally advanced, primarily inoperable pancreatic cancer | ||
Medical condition: locally advanced, primarily inoperable pancreatic carcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2022-001876-32 | Sponsor Protocol Number: SLN360-002 | Start Date*: 2023-04-14 | ||||||||||||||||
Sponsor Name:Silence Therapeutics plc | ||||||||||||||||||
Full Title: A multi-centre, randomised, double-blind placebo-controlled, Phase 2 study to investigate efficacy, safety and tolerability of SLN360 in participants with elevated lipoprotein(a) at high risk of at... | ||||||||||||||||||
Medical condition: elevated lipoprotein (a) and high risk of atherosclerotic cardiovascular disease (ASCVD) events | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) NL (Completed) SK (Completed) DK (Completed) CZ (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-001689-41 | Sponsor Protocol Number: RR11/9858 | Start Date*: 2013-11-20 | ||||||||||||||||||||||||||
Sponsor Name:University of Leeds | ||||||||||||||||||||||||||||
Full Title: Pain Reduction with Oral Methotrexate in knee Osteoarthritis, a pragmatic phase III trial of Treatment Effectiveness | ||||||||||||||||||||||||||||
Medical condition: Knee osteoarthritis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004825-14 | Sponsor Protocol Number: D1680C00016 | Start Date*: 2016-05-04 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A 24-Week, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Effects of Saxagliptin, Saxagliptin Combined with Dapagliflozin, and Sitagliptin in Pat... | |||||||||||||
Medical condition: Patients with type 2 diabetes mellitus and heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) HU (Completed) BG (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001087-10 | Sponsor Protocol Number: ELA-0121 | Start Date*: 2022-11-21 | |||||||||||
Sponsor Name:Stemline Therapeutics, Inc | |||||||||||||
Full Title: An Open-label Multicenter Phase 1b-2 Study of Elacestrant as Monotherapy and in Combination with Abemaciclib in Women and Men with Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative B... | |||||||||||||
Medical condition: Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) IT (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004214-14 | Sponsor Protocol Number: P311-201 | Start Date*: 2016-10-13 | ||||||||||||||||
Sponsor Name:Upsher-Smith Laboratories, Inc. | ||||||||||||||||||
Full Title: A Phase 1/2 Dose-escalation of USL311 as Single Agent and in Combination with Lomustine (CCNU) in Subjects with Advanced Solid Tumors, with Subsequent Single Agent and Combination Phase 2 Cohorts f... | ||||||||||||||||||
Medical condition: Advanced Solid Tumors/Relapsed/Recurrent Glioblastoma Multiforme (GBM) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-001990-22 | Sponsor Protocol Number: 54767414LEU2002 | Start Date*: 2021-08-09 | |||||||||||
Sponsor Name:Hellenic Society of Haematology (HSH) | |||||||||||||
Full Title: An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination with... | |||||||||||||
Medical condition: Primary plasma cell leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000699-39 | Sponsor Protocol Number: FGCL-3019-094 | Start Date*: 2021-11-04 | |||||||||||
Sponsor Name:FibroGen, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination with Systemic Corticosteroids in Ambulatory Subjects with Duchenne Muscular Dystrophy (DMD) | |||||||||||||
Medical condition: Ambulatory Duchenne Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) AT (Prematurely Ended) NL (Completed) IT (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004431-79 | Sponsor Protocol Number: CC-90001-NASH-001 | Start Date*: 2019-11-15 |
Sponsor Name:Celgene Corporation | ||
Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSEFINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-90001 IN SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND LIVE... | ||
Medical condition: Confirmed diagnosis of NASH and Stage 3 or Stage 4 fibrosis based upon the NASH Clinical Research Network (CRN) Histologic Scoring System and a nonalcoholic fatty liver disease (NAFLD) Activity Sco... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) ES (Ongoing) PL (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-002605-22 | Sponsor Protocol Number: KZR-616-003 | Start Date*: 2020-01-28 | |||||||||||
Sponsor Name:Kezar Life Sciences, Inc. | |||||||||||||
Full Title: A Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients with Active Polymyositis or Dermatomy... | |||||||||||||
Medical condition: Autoimmune Disorders Polymyositis and Dermatomyositis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002962-37 | Sponsor Protocol Number: NA_00008675 | Start Date*: 2010-09-14 |
Sponsor Name:VU Medical Center Amsterdam | ||
Full Title: Phase I/II study of dalteparin, a low molecular weight heparin (LMWH), in combination with Sunitinib (SU11248), an oral, selective multitargeted tyrosine kinase inhibitor, as first line treatment, ... | ||
Medical condition: Patients with metastatic or inoperable renal cell cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-011740-19 | Sponsor Protocol Number: GS-US-205-0127 | Start Date*: 2015-02-02 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: Phase 3b Randomized, Double-Blind, Placebo-Controlled Two-Part Trial to Assess the Safety and Efficacy of Continuous Aztreonam for Inhalation Solution (AZLI) in Subjects with Cystic Fibrosis (CF) a... | |||||||||||||
Medical condition: Cystic Fibrosis subjects with chronic Burkholderia spp. infection of the airways. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001955-54 | Sponsor Protocol Number: BMN-051-302 | Start Date*: 2015-12-08 | |||||||||||
Sponsor Name:BioMarin Nederland BV | |||||||||||||
Full Title: An open-label extension study of the long-term safety, tolerability and efficacy of drisapersen in subjects with Duchenne Muscular Dystrophy. | |||||||||||||
Medical condition: Duchenne Muscular Dystrophy (DMD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: NL (Prematurely Ended) DE (Completed) BE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000175-13 | Sponsor Protocol Number: FIL_PanAL10 | Start Date*: 2011-04-26 | |||||||||||
Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS | |||||||||||||
Full Title: A phase II study of oral Panobinostat in adult patients with relapsed/refractory diffuse large B-cell lymphoma after high-dose chemotherapy with autologous stem cell transfusion (ASCT) or in adult... | |||||||||||||
Medical condition: Patient has a history of DLBCL according to the WHO classification. with progressive disease after receiving at least CHOP-R or CHOP-R like first line regimen and is not considered eligible for in... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004389-37 | Sponsor Protocol Number: FG001-CT-002 | Start Date*: 2022-03-24 | |||||||||||
Sponsor Name:FluoGuide A/S | |||||||||||||
Full Title: An open-label, non-randomized, single dose, exploratory Phase II trial of FG001 (an imaging agent) for localization of biopsy-proven primary non-small cell lung cancer (NSCLC) | |||||||||||||
Medical condition: Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-006144-18 | Sponsor Protocol Number: FIRE-9/PORT | Start Date*: 2021-10-05 | |||||||||||
Sponsor Name:Charité Universitätsmedizin Berlin | |||||||||||||
Full Title: Post-resection/ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418) Prospective, randomized, open, multicenter Phase III trial to investigate the eff... | |||||||||||||
Medical condition: Metastatic colorectal cancer after definite interventional therapy of all lesions | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004451-38 | Sponsor Protocol Number: A6181092 | Start Date*: 2007-02-02 | |||||||||||
Sponsor Name:PFIZER | |||||||||||||
Full Title: A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND BRAIN METASTASES | |||||||||||||
Medical condition: Non-Small Cell Lung Cancer NSCLC patients with brain metastases | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) FR (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003371-34 | Sponsor Protocol Number: CDI-CS-002 | Start Date*: 2015-02-20 | ||||||||||||||||
Sponsor Name:Basilea Pharmaceutica International Ltd. | ||||||||||||||||||
Full Title: An open-label Phase 1/2a study of oral BAL101553 in adult patients with advanced solid tumors and in adult patients with recurrent or progressive glioblastoma or high-grade glioma | ||||||||||||||||||
Medical condition: Advanced or recurrent solid tumors, recurrent or progressive glioblastoma, or high-grade glioma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-004566-13 | Sponsor Protocol Number: EMR62206-017 | Start Date*: 2007-03-06 | |||||||||||
Sponsor Name:MERCK KGaA | |||||||||||||
Full Title: An open-label, randomised, phase II study in subjects with extensive disease, small cell lung cancer (ED-SCLC) after an initial response (complete response or partial response) to platinum-based th... | |||||||||||||
Medical condition: extensive disease, small cell lung cancer (ED-SCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001985-86 | Sponsor Protocol Number: JX594-HEP024 | Start Date*: 2016-09-29 | |||||||||||
Sponsor Name:SillaJen Inc. | |||||||||||||
Full Title: A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carc... | |||||||||||||
Medical condition: Advanced Hepatocellular Carcinoma (HCC) without prior systemic therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) PT (Prematurely Ended) PL (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
